## Edgar Filing: ENDOCYTE INC - Form 4

Form 4												
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION									PPROVAL 3235-0287			
Check th if no long subject to Section 1 Form 4 o Form 5 obligation may cont <i>See</i> Instru 1(b).	6. Filed pur Section 17(	Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940								Expires:January 31, 2005Estimated average burden hours per response0.5		
(Print or Type I	Responses)											
1. Name and A Brinkley Mi		2. Issuer Name <b>and</b> Ticker or Trading Symbol					5. Relationship of Reporting Person(s) to Issuer					
			ENDOCYTE INC [ECYT]					(Check all applicable)				
(Last) 3000 KENT A1-100	(1	3. Date of Earliest Transaction (Month/Day/Year) 07/05/2013					Director 10% Owner X Officer (give title Other (specify below) below) VP OF QUALITY ASSURANCE					
				4. If Amendment, Date Original Filed(Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person				
WEST LAF	AYETTE, IN 47	906							y More than One R			
(City)	(State)	(Zip)	Tabl	e I - Non-I	Derivative	Secu	rities A	cquired, Disposed	of, or Beneficia	lly Owned		
	2. Transaction Date (Month/Day/Year)		ate, if /Year)	3. Transaction Code (Instr. 8) Code V	Disposed (Instr. 3, 4	(A) or of (D) 4 and 2 (A) or	) 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Reminder: Rep	ort on a separate line	e for each class	s of secu	rities benef	-		-	or indirectly.	ection of	SEC 1474		

information contained in this form are not (9-02) required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of	8
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transactio	orDerivative	Expiration Date	Underlying Securities	D
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)	S

## Edgar Filing: ENDOCYTE INC - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Yea	ar) (Instr. 8)	Acquired ( or Dispose (D) (Instr. 3, 4, and 5)	ed of			(	
				Code V	(A)	(D) Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to buy)	\$ 16.42	07/05/2013		А	28,000	<u>(1)</u>	07/05/2023	Common Stock	28,000	
Reporting Owners										
Rend	orting Owner Na	ame / Address			Relatio					
Керс			Director 1	0% Owner	Officer		(	Other		
Brinkley Michael A. 3000 KENT AVENUE, SUITE A1-10 WEST LAFAYETTE, IN 47906			)	VP OF QUALITY ASSURANCE						
Signa	tures									
/s/ Beth A Taylor Attorney-in-fact for Michael A Brinkley (nower of attorney previously										

 /s/ Beth A. Taylor, Attorney-in-fact for Michael A. Brinkley (power of attorney previously filed)
 07/08/2013

 \_\_\_\_\_Signature of Reporting Person
 Date

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Shares subject to the option vest 1/4 annually over a period of 4 years beginning on July 5, 2014.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

(